Clinsights: Making Information A Competitive Advantage
Clinsights uses advanced information systems technology to aggregate population-based clinical outcomes data, and to disseminate this data to device companies and physicians. The company's data collection services include e-registries for clinical research, outcomes databases at key clinical centers, and post-market surveillance studies, and the information is disseminated through specialty websites and Internet-based data systems.Key to Clinsights' approach is building relationships with thought leaders in different clinical specialties, the first of which is interventional cardiology. In this area, Clinsights is working with the Cardiovascular Research Foundation (CRF), sponsors of the leading interventional cardiology conference, the Transcatheter Cardiovascular Therapeutics (TCT) meeting. This partnership has produced Clinsights' first website, TCTMD.com.Clinsights' bet is that it can convince medical device companies of the value of its services, built around the ability to collect and disseminate information, and enhanced by partnerships with leading physicians, in providing a competitive advantage that can help differentiate products and technologies.
by Stephen Levin
Product development and innovation in the medical device industry used to be a somewhat haphazard, off-hand process. It was not unusual for an executive working at one company to take...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
